Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GPR142 | Q7Z601 | 3/20 | 0.43 |
| ▸ | BRAF | P15056 | 10/20 | 0.39 |
| ▸ | ABL1 | P00519 | 4/20 | 0.38 |
| ▸ | BCR | P11274 | 4/20 | 0.38 |
| ▸ | TP53 | P04637 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4013972 | 0.91 | GPR142 (0.42) | GPR142BRAFABL1BCR | |
| SCHEMBL4013976 | 0.83 | FLT3 (0.35) | GPR142BRAFABL1BCR | |
| SCHEMBL3527932 | 0.82 | TP53 (0.48) | GPR142BRAFABL1BCRTP53 | |
| SCHEMBL3527702 | 0.82 | GPR142 (0.40) | GPR142BRAF | |
| SCHEMBL3533111 | 0.80 | GPR142 (0.54) | GPR142BRAFABL1BCR | |
| SCHEMBL13843768 | 0.78 | SMN1; SMN2 (0.39) | GPR142BRAFABL1BCR | |
| SCHEMBL4032069 | 0.78 | BRAF (0.45) | GPR142BRAF | |
| SCHEMBL4031152 | 0.77 | BRAF (0.43) | GPR142BRAF | |
| SCHEMBL21611777 | 0.77 | GPR142 (0.66) | GPR142BRAFTP53 | |
| SCHEMBL4014724 | 0.75 | BRAF (0.43) | GPR142BRAF |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7858804-B2 | Process for making cytokine inhibiting compounds containing 4- and 5-imidazolyl rings and the intermediates thereof | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2010-12-28 | — | — | US | disclosed |
| US-20090137815-A1 | Process for Making Cytokine Inhibiting Compounds Containing 4- and 5-Imidazolyl Rings and the Intermediates Thereof | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2009-05-28 | — | — | US | disclosed |
| EP-2010522-A1 | PROCESS FOR MAKING CYTOKINE INHIBITING COMPOUNDS CONTAINING 4- AND 5- IMIDAZOLYL RINGS AND THE INTERMEDIATES THEREOF | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2009-01-07 | — | — | EP | disclosed |
| WO-2007121390-A1 | PROCESS FOR MAKING CYTOKINE INHIBITING COMPOUNDS CONTAINING 4- AND 5- IMIDAZOLYL RINGS AND THE INTERMEDIATES THEREOF | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2007-10-25 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090137815-A1 | Process for Making Cytokine Inhibiting Compounds Containing 4- and 5-Imidazolyl Rings and the Intermediates Thereof | MIF, IL4, IL4I1 | GPR142 3493/4885BRAF 2828/4885ABL1 1201/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.